Ferrer to distribute DiaGenic test in Europe and Latin America
This article was originally published in Clinica
Executive Summary
Personalised medicine specialist Ferrer inCode (Barcelona, Spain) is to become the exclusive distributor of DiaGenic’s ADtect test for early diagnosis of Alzheimer’s disease in 32 countries across Europe and Latin America. Ferrer, which is part of pharmaceutical device group Grupo Ferrer International, will market and sell ADtect in key European markets such as Germany, the Netherlands, France, Spain and Italy. ADtect differs to other Alzheimer’s tests, as it uses peripheral blood as the sample material to provide early, noninvasive diagnosis of the disease. According to Oslo, Norway-based DiaGenic, Alzheimer’s afflicts around 30 million people worldwide and treatment-related costs were estimated at $315bn in 2005.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals